소동물 이미징 시장 : 구성 요소, 모달리티, 동물 유형, 자동화 레벨, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Small Animal Imaging Market is projected to grow by USD 2.59 billion at a CAGR of 7.89% by 2032.

Small animal imaging is a core enabler of preclinical research, allowing scientists to visualize anatomy, physiology, pharmacokinetics, biodistribution, and disease progression in living rodents and other laboratory models. Modalities such as micro-CT, micro-MRI, PET, SPECT, optical imaging, photoacoustic imaging, and high-frequency ultrasound reduce reliance on terminal endpoints by supporting longitudinal study designs aligned with the 3Rs principles of replacement, reduction, and refinement.

Demand is supported by sustained biomedical R&D, oncology and neuroscience pipelines, gene and cell therapy development, and the need for translational evidence before human trials. As regulatory and funding bodies continue emphasizing reproducibility, quantitative imaging biomarkers, and ethical animal use, preclinical imaging platforms are becoming strategic infrastructure for pharmaceutical companies, contract research organizations, academic medical centers, and biotechnology innovators.

Transformative Shifts in the Preclinical Imaging Landscape

The landscape is shifting from standalone imaging instruments toward integrated preclinical imaging ecosystems. Researchers increasingly combine anatomical imaging from micro-CT or MRI with functional readouts from PET, SPECT, fluorescence, bioluminescence, and ultrasound to improve disease characterization and therapeutic response assessment. Hybrid systems and co-registration workflows are improving data comparability across time points and study sites.

Another major shift is the move toward standardized protocols, automated image analysis, and translational biomarkers that can bridge animal studies with clinical imaging endpoints. At the same time, concerns about radiation dose, anesthesia effects, animal welfare, and data reproducibility are reshaping purchasing decisions and encouraging investment in lower-dose scanners, better monitoring systems, and validated imaging analytics.

Cumulative Impact of Artificial Intelligence on Small Animal Imaging

Artificial intelligence is changing small animal imaging by accelerating image reconstruction, segmentation, registration, denoising, and quantitative biomarker extraction. In micro-CT and MRI, AI-assisted workflows can support faster analysis and more consistent anatomical measurements. In PET, SPECT, optical, and ultrasound imaging, machine learning helps detect subtle signal changes, improve lesion tracking, and reduce observer variability in longitudinal studies.

The cumulative impact is operational as well as scientific. AI can shorten study turnaround, improve quality control, and help research teams manage large multimodal datasets. However, adoption depends on transparent model validation, bias assessment, audit trails, and fit-for-purpose performance evidence, especially when imaging outputs influence candidate selection, toxicology interpretation, or translational decision-making.

Key Regional Insights Across Global Small Animal Imaging Markets

North America remains a leading hub for small animal imaging due to strong public biomedical research funding, a dense pharmaceutical and biotechnology ecosystem, and advanced preclinical core facilities in the United States and Canada. Europe benefits from established academic imaging networks, EU research programs, and strict animal welfare frameworks, including the principles embedded in Directive 2010/63/EU, which encourage refined, longitudinal imaging approaches. The United Kingdom, Germany, France, Italy, and Spain support demand through translational medicine, oncology, neuroscience, and cardiovascular research.

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in life sciences infrastructure, biopharmaceutical innovation, and university-based imaging platforms. Latin America, led by Brazil and Mexico, is building capacity through public research institutions and clinical-translational collaborations. The Middle East shows selective momentum, particularly in GCC countries investing in biomedical research centers, genomics, and research hospitals, while Africa is advancing through university hospitals, infectious disease research programs, and international scientific partnerships.

Key Group Insights for Strategic Prioritization

ASEAN countries are strengthening preclinical research through expanding university networks, biomedical parks, and clinical research ambitions, with Singapore serving as a regional anchor for advanced life sciences infrastructure and translational research. The GCC is investing in research hospitals, genomics programs, and innovation districts, creating selective opportunities for small animal imaging in oncology, metabolic disease, neuroscience, and regenerative medicine research.

The European Union remains influential because its animal research directive, Horizon Europe framework, and cross-border research networks support standardized, welfare-conscious imaging. BRICS markets, particularly China, India, and Brazil, are important for adoption as domestic biopharma capabilities mature and public research infrastructure expands. G7 countries lead in funding depth, advanced laboratory capacity, and translational imaging expertise, while NATO member states benefit from broader biomedical, defense health, infectious disease, and advanced technology research ecosystems.

Key Country Insights in Small Animal Imaging Adoption

The United States leads through strong federal biomedical research funding, a large biopharma base, and specialized preclinical imaging core facilities. Canada supports adoption through academic health sciences networks and translational research centers, while Mexico and Brazil are expanding Latin American capacity through public universities, research institutes, and pharmaceutical development activities. In Europe, the United Kingdom, Germany, France, Italy, and Spain sustain small animal imaging adoption through oncology, cardiovascular, neuroscience, inflammation, and infectious disease research, while Russia maintains selective capability through major scientific and medical research institutes.

China is scaling rapidly through domestic biopharma investment, national science programs, and expanding laboratory infrastructure. India is gaining momentum through pharmaceutical R&D, contract research, and academic medicine. Japan and South Korea maintain strong demand for high-precision imaging in regenerative medicine, oncology, drug discovery, and advanced biomedical engineering, while Australia combines university research strength, biomedical clusters, and rigorous ethics governance to support high-quality preclinical imaging workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize multimodal platforms, validated image analysis software, and service models that reduce workflow complexity for researchers. Vendors can strengthen competitiveness by offering application-specific protocols for oncology, neurology, cardiovascular disease, inflammation, pharmacokinetics, biodistribution, and cell tracking, supported by training, preventive maintenance, and reproducibility documentation.

Pharmaceutical companies, CROs, and academic centers should invest in standardized acquisition protocols, animal monitoring, data governance, and AI validation frameworks. Strategic partnerships with universities, imaging core facilities, and biomarker consortia can improve translational relevance. Commercial teams should localize offerings by region, aligning premium systems with mature research markets and scalable, service-backed configurations with emerging research hubs.

Research Methodology for Evidence-Based Analysis

This executive summary is developed using a structured secondary research approach grounded in publicly available and institutionally recognized sources, including government science agencies, regulatory guidance, peer-reviewed academic literature, animal welfare frameworks, and life sciences industry disclosures. The analysis considers technology adoption patterns across micro-CT, MRI, PET, SPECT, optical imaging, photoacoustic imaging, and high-frequency ultrasound.

Insights were synthesized through triangulation across demand drivers, research funding trends, regulatory requirements, modality applications, regional innovation capacity, and end-user needs. Emphasis was placed on verified, data-backed evidence rather than speculative claims, with qualitative assessment used where comparable public datasets are limited across geographies and preclinical imaging use cases.

Conclusion: Future Outlook for Small Animal Imaging

Small animal imaging is becoming indispensable to translational research because it enables noninvasive, longitudinal, and quantitative evaluation of disease biology and therapeutic response. As drug discovery grows more complex and ethical expectations increase, imaging technologies that improve reproducibility, reduce animal numbers, and generate clinically relevant biomarkers will remain central to preclinical decision-making.

Future advantage will depend on integrated systems, AI-enabled analytics, validated workflows, and regional strategies aligned with research maturity. Organizations that combine scientific rigor with scalable technology, strong service support, and responsible animal research practices will be best positioned to advance adoption across the global small animal imaging landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Small Animal Imaging Market, by Component

• 7.1. Equipment
• 7.2. Reagents & Consumables
• 7.3. Software
• 7.4. Services
  • 7.4.1. Imaging Services
  • 7.4.2. Maintenance & Support
  • 7.4.3. Training Services

8. Small Animal Imaging Market, by Modality

• 8.1. Computed Tomography
• 8.2. Magnetic Resonance Imaging
• 8.3. Optical Imaging
  • 8.3.1. Bioluminescence Imaging
  • 8.3.2. Fluorescence Imaging
  • 8.3.3. Cerenkov Luminescence Imaging
• 8.4. Nuclear Imaging
• 8.5. Ultrasound Imaging

9. Small Animal Imaging Market, by Animal Type

• 9.1. Rodents
  • 9.1.1. Mice
  • 9.1.2. Rats
• 9.2. Rabbits
• 9.3. Zebrafish
• 9.4. Zebrafish

10. Small Animal Imaging Market, by Automation Level

• 10.1. Manual Systems
• 10.2. Semi-Automated Systems
• 10.3. Fully Automated Systems

11. Small Animal Imaging Market, by Application

• 11.1. Cardiology
• 11.2. Drug Discovery & Development
  • 11.2.1. Pharmacokinetics
  • 11.2.2. Pharmacodynamics
• 11.3. Neurology
  • 11.3.1. Brain Mapping
  • 11.3.2. Neurodegenerative Disease Studies
• 11.4. Oncology
  • 11.4.1. Tumor Detection
  • 11.4.2. Tumor Progression Monitoring
• 11.5. Inflammation & Immunology

12. Small Animal Imaging Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Contract Research Organizations
• 12.3. Hospitals & Clinics
• 12.4. Pharmaceutical & Biotechnology Companies

13. Small Animal Imaging Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Small Animal Imaging Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Small Animal Imaging Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Advanced Molecular Vision, Inc.
• 17.2. Aspect Imaging Ltd.
• 17.3. Berthold Technologies GmbH & Co. KG
• 17.4. Bruker Corporation
• 17.5. Cubresa Inc.
• 17.6. FUJIFILM VisualSonics, Inc.
• 17.7. General Electric Company
• 17.8. IVIM Technology, Inc.
• 17.9. LI-COR Biosciences, Inc.
• 17.10. Medikors Inc.
• 17.11. Mediso Ltd.
• 17.12. MR Solutions Ltd.
• 17.13. Optiscan Imaging Ltd
• 17.14. Revvity, Inc.
• 17.15. Rigaku Corporation
• 17.16. Scanco Medical AG
• 17.17. Sedecal S.A.
• 17.18. Siemens Healthineers AG
• 17.19. Thermo Fisher Scientific Inc.
• 17.20. TriFoil Imaging, Inc.
• 17.21. Vieworks Co., Ltd.